Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments

Jeffry Bieber; Arthur Kavanaugh

doi:10.1016/j.rdc.2004.01.003

Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments

Rheum Dis Clin North Am. 2004 May;30(2):257-70, v. doi: 10.1016/j.rdc.2004.01.003.

Authors

Jeffry Bieber¹, Arthur Kavanaugh

Affiliation

¹ Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California at San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA.

PMID: 15172039
DOI: 10.1016/j.rdc.2004.01.003

Abstract

Evidence supports the association of tuberculosis (TB) with tumor necrosis factor inhibitor therapy in patients who have rheumatoid arthritis. There seem to be differential risks of TB with the currently available inhibitors. Screening for latent TB infection with purified protein derivative is indicated for patients who are being considered for treatment; it seems to be effective in reducing the occurrence of TB in treated patients.

Publication types

Review

MeSH terms

Antirheumatic Agents / adverse effects*
Antitubercular Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / immunology
Biological Therapy / adverse effects*
Humans
Risk
Tuberculosis / drug therapy*
Tuberculosis / etiology
Tuberculosis / immunology
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Tumor Necrosis Factor-alpha / immunology

Substances

Antirheumatic Agents
Antitubercular Agents
Tumor Necrosis Factor-alpha